2025 ASCO® Annual Meeting

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

01:42 PM

Duration 6mins United States

Fixed duration subcutaneous (SC) mosunetuzumab▼ (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL): interim results from the Phase II MorningSun study

Flinn IW, Burke JM, Sharman JP, Anz B, Zuniga R, Tun AM, Jani P, Biondo JML, Wu M, Mun Y, Chopra VS, Farighi R, Lin T, Villasboas JC, Budde LE

Oncology - Hematology | Follicular Lymphoma

02:00 PM

Duration 180mins Chicago, USA

Updated Efficacy and Safety of Entrectinib▼ in Children with Extracranial Solid or Primary Central Nervous System (CNS) Tumors Harboring ROS1 Fusions

A. Desai, H. Wang, E. Basu, M. Casanova, A. Armstrong, D. Morgenstern, C. Pratilas, A. Cardenas, T. Barata, C. E. Devlin, K. E. Hutchinson, F. Wu, J. Wulff, A. Gajjar, E. Fox

Oncology | Solid Tumors

Duration 180mins Chicago, USA

Risk factors (RF) for brain metastases (BM) in patients (pts) with metastatic breast cancer (MBC): An analysis of US electronic health records (EHRs)

Leone JP, Sammons S.L, Lamert P, Huang Y, Montemurro F, Shivhare M, Restuccia E, Knott A, Sanglier T, Tolaney S.M, Lin N.U

Oncology | Breast Cancer

Duration 180mins Chicago, USA

Preliminary Safety, Pharmacokinetics, and Clinical Activity of Mosperafenib (RG6344) in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer

E. Fontana, M. Vieito, E. Castanon, I. Matos, O. Bechter, I. Moreno, C. Han, RL. Eefsen, DJ. Pinato, R. Plummer, H. Prenen, G. Schnetzler, P. Pettazzoni, D. Dejardin, A. Keelara, E. Cinato, N. Flinn, NA. Kratochwil, A. Roller, N. Keshelava

Oncology | Gastrointestinal Cancer

Duration 6mins United States

Glofitamab▼ plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2 year (yr) follow up of STARGLO

Abramson JS, Ku M, Hertzberg M, Fox CP, Herbaux C, Huang H-Q, Yoon DH, Kim WS, Zhang H, Abdulhaq H, Townsend W, Mulvihill E, Orellana-Noia V, Ta R, Huang H, Kallemeijn M, Belousov A, Bottos A, Lundberg L, Gregory G

Oncology - Hematology | Diffuse large B cell lymphoma

06:30 PM

Duration 180mins Chicago, USA

Krascendo 2: a phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC)

Skoulidis F, Solomon B, Popat S, Frost N, Heist R, Zhou C, Zarak Crnkovic M, Antic V, Prizant H, Mayo MC Meyenberg C, Keufer-Le Gall S

Oncology | Lung Cancer

Duration 180mins Chicago, USA

IMpower010: Genomic Profiling and Clinical Outcomes With Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer (eNSCLC)

Heather A. Wakelee, Enriqueta Felip, Caicun Zhou, Eric Vallières, Martin Reck, Nasser Altorki, Achim Rittmeyer, Tibor Csoszi, Ihor Vynnychenko, Antonio Chella, Velimir Gayevskiy, Wei Zou, Barbara Gitlitz, Marcus Ballinger, Elizabeth Bennett, Barzin Y. Nabet, Minu K. Srivastava

Oncology | Non-Small Cell Lung Cancer

07:19 PM

Duration 12mins United States

Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2- LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts

Oliveira M, Accordino M, Cervantes A, Gambardella V, Hamilton E, Italiano A, Jhaveri K, Juric D, Kalinsky K, Krop I, Saura C, Schmid P, Turner N C, Varga A, Jin Y, Lim S, Royer-Joo S, Shankar N, Schutzman J, Bedard P

Oncology | Breast Cancer

02:00 PM

Duration 180mins Chicago, USA

Meeting diversity enrollment targets in IMbrave152/SKYSCRAPER-14, a global phase 3 study in patients with unresectable hepatocellular carcinoma (HCC)

Cotter C, Bhagat R, Bulhan H, Leon P, Lin L, Richie N, Sims R, Spahn J, Stamatis M, Yalovsky L, Zhu H, Ibrahim Y

Oncology | Lung Cancer

02:00 PM

Duration 180mins Chicago, USA

Giredestrant (G) with atezolizumab (ATEZO), and/or abemaciclib (ABEMA) in patients (pts) with ER+/HER2- locally advanced/metastatic BC (LA/mBC): Interim analysis (IA) from the phase I/II MORPHEUS Breast Cancer (BC) study

Oliveira M, Sonnenblick A, Stemmer S, Cortes Gion M, Im SAH, Bermejo De Las Heras B, Gal Yam E, Sohn JH, Wander S, Rugo HS, Park Y, Cahuzac C, Collier A, Ngo H, Retiere AC, Schwab R, Zhu J, Jung KH

Oncology | Breast Cancer

Duration 180mins Chicago, USA

Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity

S.A. IM, G. Alonso Casal, I. Moreno, R. Kristoffer, V. Gambardella, A. Italiano, S. Lim, S. Cheeti, P. Yu, A. Swat, F. Amair-Pinedo, D. Juric

Oncology | Breast Cancer

06:30 PM

Duration 180mins Chicago, USA

Impact of proton pump inhibitor (PPI) pharmacogenomics (PGx) on toxicities associated with immune checkpoint inhibitor (ICI) therapy

Kennedy LC, Mohindra R, Sharpe JM, Mycroft SL, Balko JM, Chandler SG, Lyalina S

Oncology | Solid Tumors

10:00 PM

Duration 12mins Arie Crown Theater

Lurbinectedin + atezolizumab as first-line maintenance treatment in patients with extensive-stage small cell lung cancer: Primary results of the Phase 3 IMforte trial

L Paz-Ares, H Borghaei, S Liu, S Peters, R Herbst, K Stencel, M Majem, G Czyzewic, R Bernabe Caro, K H Lee, M Johnson, N Karadurmus, C Grohe, V Cuchelkar, V Graupner, M Kaul, L Lin, D Chakrabarti, K Bhatt, M Reck

Oncology | Lung Cancer

I am a healthcare professional

Notice

Cookies

External site

2025 ASCO® Annual Meeting